Back
Corcept Therapeutics Quote, Financials, Valuation and Earnings
Sponsored
CORT
Sponsored
20 Most Hated Stocks on Wall Street
Click here to see the full list and protect yourself before it's too late.
Buy
62
CORT
Corcept Therapeutics
Last Price:
24.20
Seasonality Move:
4.21%
7 Day Trial
ALL ACCESS PASS
$
7
7 Powerhouse Stocks to Buy and Hold Forever
Get it now.Corcept Therapeutics Price Quote
$24.20
-0.88 (-3.51%)
(Updated: May 3, 2024 at 2:20 PM ET)
Corcept Therapeutics Key Stats
Buy
62
Corcept Therapeutics (CORT)
is a Buy
Day range:
$23.80 - $26.39
52-week range:
$20.84 - $34.28
Dividend yield:
0%
P/E ratio:
26.68
P/S ratio:
5.81
P/B ratio:
5.12%
Volume:
2.1M
Avg. volume:
1.1M
1-year change:
12.01%
Market cap:
$2.6B
Revenue:
$482.4M
EPS:
$0.95
How Much Does Corcept Therapeutics Make?
-
How Much Are Corcept Therapeutics's Sales Annually?
CORT Revenues are $482.4M -
How Much Profit Does Corcept Therapeutics's Make A Year?
CORT net income is $106.1M
Is Corcept Therapeutics Growing As A Company?
-
What Is Corcept Therapeutics's Growth Rate Quarterly?
Quarterly YoY revenue growth is 0.31% -
What Is Corcept Therapeutics's EPS Quarterly YoY Growth Rate?
Quarterly, year-over-year diluted EPS growth rate is 1%
Corcept Therapeutics Stock Price Performance
-
Did Corcept Therapeutics Stock Go Up Last Month?
Corcept Therapeutics share price went down by -1.1% last month -
Did CORT's Share Price Rise Over The Last Year?
CORT share price rose by 12.01% over the past 1 year
What Is Corcept Therapeutics 52-Week High & Low?
-
What Is Corcept Therapeutics’s 52-Week High Share Price?
Corcept Therapeutics has traded as high as $34.28 over the past 52 weeks -
What Is Corcept Therapeutics’s 52-Week Low Share Price?
Corcept Therapeutics has traded as low as $20.84 over the past 52 weeks
Corcept Therapeutics Price To Free Cash Flow
-
Is Corcept Therapeutics Stock Overvalued?
Corcept Therapeutics is trading at a price to free cash flow ratio of 22.08 -
Is Corcept Therapeutics Stock Undervalued?
Corcept Therapeutics EV to Free Cash Flow ratio is 17.56 -
What Is Corcept Therapeutics’s Price Earnings Growth Ratio?
CORT PEG ratio is 3.32 -
Is Corcept Therapeutics Trading At A Premium To Earnings?
Corcept Therapeutics EV to EBIT ratio is 20.77
Is It Risky To Buy Corcept Therapeutics?
-
How Much Debt Does Corcept Therapeutics Have?
Total long term debt quarterly is $0 -
How Much Cash Does Corcept Therapeutics Have?
Cash and short term investments quarterly total is $368.2M -
What Is Corcept Therapeutics’s Book Value Per Share?
Book value per share is 4.90
Is Corcept Therapeutics Cash Flow Positive?
-
What Is CORT Cash Flow From Operations?
Cash flow from operations (TTM) is $127M -
What Is Corcept Therapeutics’s Cash Flow From Financing?
Cash flow from financing (TTM) is -$148.7M -
What Is Corcept Therapeutics’s Cash Flow From Investing?
Cash flow from investing (TTM) is $90.9M
Corcept Therapeutics Return On Invested Capital
-
Is Management Doing A Good Job?
CORT return on invested capital is 21.92% -
What Is Corcept Therapeutics Return On Assets?
ROA measures how assets are converting to revenues and is 18.04% -
What Is CORT Return On Equity?
ROE is a measure of profitability and is 21.92%
Corcept Therapeutics Earnings Date & Stock Price
-
What Is Corcept Therapeutics's Stock Price Today?
A single share of CORT can be purchased today for 25.08 -
What Is Corcept Therapeutics’s Stock Symbol?
Corcept Therapeutics trades on the nasdaq under the ticker symbol: CORT -
When Is Corcept Therapeutics’s Next Earnings Date?
The next quarterly earnings date for Corcept Therapeutics is scheduled on August 2, 2024 -
When Is CORT's next ex-dividend date?
Corcept Therapeutics's next ex-dividend date is May 3, 2024 -
How To Buy Corcept Therapeutics Stock?
You can buy Corcept Therapeutics shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
Corcept Therapeutics Competitors
-
Who Are Corcept Therapeutics's Competitors?
Below is a list of companies who compete with Corcept Therapeutics or are related in some way:
Corcept Therapeutics Dividend Yield
Data Unavailable
Corcept Therapeutics Analyst Estimates
YoY Growth | Past Surprise | |
---|---|---|
EPS: | 100% | 13.64% |
Revenue: | 31.39% | 3.97% |
Analyst Recommendations
Buy Recommendations: | 3 |
---|---|
Hold Recommendations: | 0 |
Sell Recommendations: | 0 |
Price Target: | 43.60 |
Upside from Last Price: | 73.84% |